Context Therapeutics Q4 EPS $(0.14) Misses $(0.10) Estimate

Context Therapeutics (NASDAQ: CNTX) reported a fourth-quarter loss of $(0.14) per share, which was 34.62% worse than the analyst consensus estimate of $(0.10). This miss indicates a larger-than-expected financial shortfall for the company in this reporting period.